RSS Feeds
The Physiologic Basis for Therapy of Classic Hemophilia (Factor VIII Deficiency) and Related Disorders
Combined Clinical Staff Conference at the National Institutes of Health
- N. RAPHAEL SHULMAN, M.D.;
- DALE H. COWAN, M.D.;
- EUGENE P. LIBRE, M.D.;
- STANLEY P. WATKINS, JR., M.D.; and
- VICTOR J. MARDER, M.D.Bethesda, Maryland
- Requests for reprints should be addressed to N. Raphael Shulman, M.D., Chief, Clinical Hematology Branch, National Institute of Arthritis and Metabolic Diseases, Bldg. 10, Room 9N250, National Institutes of Health, Bethesda, Md. 20014.
Excerpt
Dr. N. Raphael Shulman: In the past few years much new information has been acquired concerning the pathophysiology and therapy of classic hemophilia and other diseases involving factor VIII deficiency. Most important has been a revolution in treatment permitted by the availability of factor VIII concentrates. Hemostasis in hemophiliacs, which several years ago presented a difficult if not hopeless problem, now can be managed with complete effectiveness in a rather routine manner. In addition, there is a clearer concept of the genetic control of factor VIII, provided chiefly by studies of von Willebrand's disease; and recently, there have been some
Article and Author Information
-
This is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Md., by the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Public Health Service, U. S. Department of Health, Education, and Welfare.
-
- Received July 27, 1967.
- Accepted August 3, 1967.
